Skip to content
Review Open access

Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials

Oct 2026 · Archives of Endocrinology and Disorders · Vol 2, pp. 1-18 · 0 citations · 9 references

TL;DR

Overall, ASIs have strong short-term placebo-adjusted effects on BP, but direct RCT comparisons between ASIs and MRAs are required; therefore, class comparison is indirect and must be interpreted cautiously.

Abstract

Background: The overproduction of aldosterone is an important cause of uncontrolled or resistant hypertension. Conversely, aldosterone synthase inhibitors including baxdrostat and lorundrostat have an upstream effect blocking aldosterone synthesis. The overproduction of aldosterone causes many drug resistant hypertensive diseases. Agents that act at the Mineralocorticoid Receptor (MR), i.e., MR Antagonists (MRAs) such as spironolactone and eplerenone block signalling downstream of aldosterone, thereby inducing BP lowering effects. Conversely, aldosterone synthase inhibitors inculding baxdrostat and lorundrostat have an upstream effect at the aldosterone level, thereby specifically reducing the production of aldosterone in the adrenal cortex. Objective: This systematic review and meta-analysis of recent (2020-2025) RCTs on blood pressure-lowering evidence for ASIs and established MRAs. The 2020-2025 records published were included in accordance with PRISMA 2020 orientation (Pubmed, Scopus, Web of Science, Cochrane CENTRAL, ClinicalTrials.gov). Eligible recent (2020-2025) randomized controlled trials in adults with hypertension reporting impact on Systolic Blood Pressure (SBP) or Diastolic Blood Pressure (DBP) were included. Placebo-adjusted mean differences in mmHg data was assessed, using random-effects meta-analysis where summary confidence intervals available. Outcomes: Eight contemporary RCT reports qualified for qualitative synthesis and five ASI RCT reports were incorporated as dose-level estimates in quantitative synthesis. The combined effect of ASI was a reduction in SBP by almost -8.82 mmHg (95% CI, -10.46 to -7.18; I2 from dose-level summaries = moderate) and a reduction in DBP by almost -4.25 mmHg (95% CI, -5.33 to -3.18). The two drugs, Baxdrostat and lorundrostat, produced clinically meaningful reductions, especially in those with uncontrolled or resistant hypertension. No new 2020-2025 RCT directly comparing spironolactone or eplerenone against ASIs was identified; therefore, class comparison is indirect and must be interpreted cautiously. Overall, ASIs have strong short-term placebo-adjusted effects on BP. MRAs are the standard add-on therapy of resistant hypertension, but direct RCT comparisons between ASIs and MRAs are required.

Read PDF

Similar papers

Review Nov 2026

Abstract 10888: Clinical Outcomes of Novel Aldosterone Synthase Inhibitors (Lorundrostat and Baxdrostat) in Low and High Dose in Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of RCTs

Background: Despite the availability of antihypertensive therapies, uncontrolled and resistant hypertension remains common, possibly driven by inappropriate aldosterone activity. Novel aldosterone synthase inhibitors (ASIs) such as Lorundrostat and Baxdrostat selectively inhibit CYP11B2, offering to reduce aldostero...

Hussain Khan, Anfal Khan, Mohammad Idrees et al. · 0 citations
Review Nov 2026

Abstract 16126: Antihypertensive Efficacy and Safety of Aldosterone Synthase (CYP11B2) Inhibitors: A GRADE-Guided Systematic Review and Meta-Analysis with Trial Sequential Analysis

Background: Persistent aldosterone-driven hypertension remains common despite established renin-angiotensin system blockade and mineralocorticoid receptor antagonism. Aldosterone synthase (CYP11B2) inhibition directly suppresses aldosterone biosynthesis, but its blood pressure (BP) effects across different agents an...

S. Ramadan, Amr M. Abou Elezz, Ahmed N. Mohamed et al. · 0 citations
Review Nov 2026

Abstract 13854: Comparative Efficacy and Safety of Aldosterone Synthase Inhibitors versus Mineralocorticoid Receptor Antagonists for Resistant Hypertension: A Systematic Review and Network Meta-Analysis

Introduction: Resistant hypertension often persists despite multidrug therapy, driven by unopposed aldosterone activity. In May 2026, the FDA approved baxdrostat, a first-in-class aldosterone synthase inhibitor. Other agents include mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone....

R. Khan, H. Ramteke, Sai Sravanth Reddy Tamma et al. · 0 citations
Review Nov 2026

Abstract 7174: Efficacy and Safety of Aldosterone Synthase Inhibitors in Controlling Treatment-Resistant Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Hypertension is a major global health burden and a leading preventable risk factor for cardiovascular morbidity and mortality, affecting approximately 1.28 billion people globally, many of whom remain inadequately controlled. Aldosterone, a key hormone involved in the pathogenesis of hypertension, has le...

Muhammad Usman Babar, Sarah Eman, Nashmia Faraz et al. · 0 citations
Review Nov 2026

Abstract 6326: Dose-Response Efficacy and Safety of the Aldosterone Synthase Inhibitor Baxdrostat in Resistant Hypertension: A Systematic Review and Network Meta-Analysis

Background: Resistant hypertension (RH) is associated with increased cardiovascular morbidity and mortality, with limited treatment options due to adverse effects and suboptimal control. Aldosterone plays a central role in RH pathophysiology, making aldosterone synthase inhibition a promising therapeutic target. Bax...

M. Shahzaib, Anza Muhammad, Hafsa Ali et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.